14067 executive order digital currency- Top Block

The new Indian central bank governor: We have made progress in inclusive finance, but there is still more work to be done; Efforts will be made to further utilize technology without stifling innovation.Eight people were killed when the Israeli army attacked a house in the central part of Gaza, and eight people were killed and many others were injured when the Israeli army bombed a house in Nuseilet refugee camp in the central part of Gaza on the evening of 10th local time.Bank of America: Resume the coverage of Lilly and give it a "buy" rating with a target price of $997.

Officials said that fighting broke out between the forces of Jubaland and the federal government in Somalia.The onshore RMB against the US dollar officially closed at 7.2590 at 16:30 Beijing time, down 97 points from the official closing price of the previous trading day and down 99 points from the closing price of the previous day and night.Morgan Asset Management: In 2025, there are sufficient reasons to continue to over-allocate US stocks. Sylvia Sheng, global multi-asset strategist of Morgan Asset Management, said that there are sufficient reasons to continue to over-allocate US stocks and increase exposure to small and medium-sized stocks. She pointed out that although the valuation may look high, it is expected that the profit growth of S&P 500 companies will continue. Sheng wrote that it is estimated that in 2025, the contribution of the six giants in the S&P 500 index to the profit growth of the other 494 stocks will be the same, and the profit growth of these six giants is expected to slow down from 40% in 2024 to 22%. In the international market, Morgan Asset Management continues to over-allocate Japanese stocks, and its quantitative model shows that the yield of Japanese stocks is attractive and the bottom-up profitability is strong.

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Market information: Trump's nominee for finance minister, Bertrand Besson, said that Federal Reserve Chairman Powell can complete his remaining term.Trump appointed TOM BARRACK as the US ambassador to Turkey.